Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Utah Medical Products (UTMD) EPS (Weighted Average and Diluted) (2016 - 2025)

Utah Medical Products has reported EPS (Weighted Average and Diluted) over the past 16 years, most recently at $0.8 for Q4 2025.

  • Quarterly results put EPS (Weighted Average and Diluted) at $0.8 for Q4 2025, down 6.98% from a year ago — trailing twelve months through Dec 2025 was $3.48 (down 12.12% YoY), and the annual figure for FY2025 was $3.48, down 12.12%.
  • EPS (Weighted Average and Diluted) for Q4 2025 was $0.8 at Utah Medical Products, down from $0.82 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for UTMD hit a ceiling of $1.25 in Q4 2022 and a floor of $0.8 in Q4 2025.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was $1.06 (2023), compared with a mean of $1.03.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): surged 161.11% in 2021 and later fell 27.12% in 2024.
  • Utah Medical Products' EPS (Weighted Average and Diluted) stood at $1.13 in 2021, then grew by 10.62% to $1.25 in 2022, then fell by 5.6% to $1.18 in 2023, then dropped by 27.12% to $0.86 in 2024, then fell by 6.98% to $0.8 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were $0.8 (Q4 2025), $0.82 (Q3 2025), and $0.94 (Q2 2025) per Business Quant data.